Acumen Pharmaceuticals, Inc. (ABOS) Form 10-Q — Oct 26, 2026
Acumen Pharmaceuticals reported a Q3 2026 net loss of $25.4 million and a nine-month net loss of $78.8 million, with $78.6 million in cash and marketable securities as of September 30, 2026. The company disclosed substantial doubt about its ability to continue as a going concern, stating its current capital will fund operations only into early 2027 and will not cover at least 12 months from the filing date. It previously raised $35.7 million gross in a March 2026 private placement at $3.30 per share and carries roughly $26.6 million of term loan principal due to K2 HealthVentures, maturing November 1, 2027.
Key figures
- Total Debt
- 26272000
- Total Assets
- 85565000
- Cash Position
- 53075000
- Shares Outstanding
- 72327320
- Term loan maturity
- 2027-11-01
- Accumulated deficit
- $525.3 million
- Altitude ad participants
- 542
- Jcr potential milestones
- up to $555.0 million
- Private placement shares
- 10833331
- Nine month r and d expense
- 65406000
- Jcr option exercise payment
- $9.25 million
- Term loan original principal
- $50.0 million ($30.0 million drawn)
- Cash plus marketable securities
- $78.6 million
- Private placement gross proceeds
- $35.7 million
- Private placement price per share
- 3.3
- Term loan effective interest rate
- 14.7% (nine months 2026)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.